Transplantation & Cellular Therapy

The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.

Chadi Nabhan, MD, MBA, FACPMeeting News | September 14, 2023
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
View More
Cecilia BrownChronic Lymphocytic Leukemia | August 30, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Cecilia BrownTransplantation & Cellular Therapy | August 29, 2023
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Cecilia BrownMantle Cell Lymphoma | August 23, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Leah SherwoodAcute Myeloid Leukemia | July 28, 2023
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Cecilia BrownPrint | July 11, 2023
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Cecilia BrownTransplantation & Cellular Therapy | April 17, 2023
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Cecilia BrownTransplantation & Cellular Therapy | April 11, 2023
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Cecilia BrownTransplantation & Cellular Therapy | April 10, 2023
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
Cecilia BrownTransplantation & Cellular Therapy | March 3, 2023
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
Cecilia BrownTransplantation & Cellular Therapy | March 2, 2023
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Cecilia BrownViewpoints | February 28, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Leah SherwoodTransplantation & Cellular Therapy | February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Cecilia BrownTransplantation & Cellular Therapy | February 10, 2023
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Cecilia BrownVideo Insights | February 8, 2023
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
Cecilia BrownMyeloma | January 25, 2023
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Cecilia BrownPrint | January 13, 2023
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Cecilia BrownTransplantation & Cellular Therapy | December 2, 2022
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Leah SherwoodAcute Lymphoblastic Leukemia | November 29, 2022
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Leah SherwoodTransplantation & Cellular Therapy | October 25, 2022
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodTransplantation & Cellular Therapy | October 11, 2022
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Cecilia BrownMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers had not previously studied the long-term impact of omidubicel...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Cecilia BrownTransplantation & Cellular Therapy | September 15, 2022
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
Cecilia BrownTransplantation & Cellular Therapy | September 15, 2022
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Leah LawrenceTransplantation & Cellular Therapy | September 13, 2022
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
A second allogeneic HSCT is a reasonable treatment option for patients with relapsed AML.
Leah SherwoodTransplantation & Cellular Therapy | August 10, 2022
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
Leah SherwoodPrint | August 9, 2022
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
Cecilia BrownPrint | August 8, 2022
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Leah SherwoodAcute Lymphoblastic Leukemia | August 8, 2022
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Advertisement
Advertisement
Advertisement
Advertisement
Latest Posts

September 22, 2023